Table of contents

Minimal change disease


Key sources

The following summarized guidelines for the evaluation and management of minimal change disease are prepared by our editorial team based on guidelines from the Kidney Disease: Improving Global Outcomes Foundation (KDIGO 2021,2012) and the Japanese Society of Nephrology (JSN 2016). ...
Show more

Classification and risk stratification

Prognosis: as per KDIGO 2021 guidelines, recognize that long-term kidney survival is excellent in patients with MCD responding to corticosteroids, but less certain for patients not responding.
Create free account

Diagnostic procedures

Kidney biopsy: as per KDIGO 2021 guidelines, perform kidney biopsy to diagnose MCD in adult patients.

Medical management

Corticosteroids: as per KDIGO 2021 guidelines, initiate high-dose corticosteroids for no longer than 16 weeks as initial treatment in adult patients with MCD unless contraindicated.
Show 2 more

More topics in this section

  • Immunosuppressants

  • Supportive therapy

Therapeutic procedures

RRT: as per KDIGO 2012 guidelines, consider initiating RRT as indicated in adult patients with MCD and AKI, together with corticosteroids as for a first episode.

Follow-up and surveillance

Assessment of treatment response: as per KDIGO 2021 guidelines, define complete remission as reduction of proteinuria to < 0.3 g/day or protein-to-creatinine ratio < 300 mg/g (or < 30 mg/mmol), stable serum creatinine and serum albumin > 3.5 g/dL (or 35 g/L).
Show 5 more

More topics in this section

  • Management of relapse (corticosteroids)

  • Management of relapse (immunosuppressants)